<DOC>
	<DOCNO>NCT00590031</DOCNO>
	<brief_summary>Patients surgically resectable T1N1M0 T2-4N M0 esophageal carcinoma receive six week induction chemotherapy weekly irinotecan cisplatin give week 1 , 2 , 4 5 . Patients receive weekly irinotecan , cisplatin , concurrent radiotherapy chemotherapy give weekly , week 8,9,11 12 six week radiotherapy . Patients refer surgery 4-8 week completion chemoradiotherapy .</brief_summary>
	<brief_title>Phase II Trial Preoperative Combined Modality Therapy Esophageal Carcinoma : Cisplatin-Irinotecan Followed Radiation Therapy With Concurrent Cisplatin Irinotecan .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patients must able sign inform consent document . Tis ( insitu carcinoma ) tumor determine TIN0 follow endoscopy , endoscopic ultrasound , CT scan . Cervical esophageal tumor , Gastric cancer minor involvement gastroesophageal junction distal esophagus . Prior chemotherapy radiation . Patients evidence metastatic disease eligible . This include : Positive malignant cytology pleura , pericardium peritoneum . Radiographic evidence distant organ involvement include lung , liver , bone , brain . Patients involvement nonregional lymph node include supraclavicular celiac lymph node metastasis . Biopsy proven tumor invasion tracheobronchial tree presence tracheoesophageal fistula . Recurrent laryngeal nerve phrenic nerve paralysis , New York Heart Association Class III 1V heart disease . Angina myocardial infarction within last 6 month , history significant ventricular arrhythmia require medication antiarrhythmic , history clinically significant conduction system abnormality . Severe comorbid condition include severe uncontrolled diabetes , uncontrolled hypertension , cerebral vascular disease , uncontrolled infection , nonmalignant illness whose control may jeopardize complication study treatment . Pregnant lactate woman ineligible effect drug use study fetus newborn child unknown . Premenopausal fertile female require negative pregnancy test prior study entry . Treatment may begin result pregnancy test ascertain . Both sex must use contraception study . History prior malignancy ( basal cell/squamous carcinoma skin , insitu cervical carcinoma , superficial transitional cell bladder carcinoma ) diagnose and/or treat within three year entrance study . Patients know Gilbert 's Disease . Clinically significant hearing loss . Serum calcium_ &gt; 12 mg/dl . Patients history seizure disorder receive phenytoin , phenobarbital , antiepileptic medication . Patients fully comprehend therapeutic implication protocol comply requirement . Patients concurrent medical psychiatric condition disease , , investigator 's judgment , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Esophageal Carcinoma</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>02-045</keyword>
</DOC>